Vanguard Investments Australia
PRAX icon

Vanguard Investments Australia’s Praxis Precision Medicines PRAX Stock Holding History

Vanguard Investments Australia’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.99M Hold
5,936
– – ﹤0.01% 918
2026
Q1 		$1.91M Buy
+5,936
New +$1.84M 0.01% 869

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Investments Australia's PRAX Position: Q2 2026 in Review

Vanguard Investments Australia held its Praxis Precision Medicines (PRAX) position steady in Q2 2026 at 5,936 shares worth $1.99M. The position accounts for ﹤0.01% of the portfolio, ranked #918.

Vanguard Investments Australia first reported a position in PRAX in Q1 2026 and has held it in 2 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Vanguard Investments Australia held 5,936 shares of Praxis Precision Medicines worth $1.99M as of Q2 2026.
  • Vanguard Investments Australia left its Praxis Precision Medicines share count unchanged in Q2 2026.
  • Praxis Precision Medicines made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #918 holding.
  • Vanguard Investments Australia first reported a position in Praxis Precision Medicines in Q1 2026 and has held it in 2 quarters since.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.